Latest news with #EOLS
Yahoo
13-05-2025
- Business
- Yahoo
Evolus, Inc. (EOLS): A Bull Case Theory
We came across a bullish thesis on Evolus, Inc. (EOLS) on Substack by Greg ┃The Elevator Pitch. In this article, we will summarize the bulls' thesis on EOLS. Evolus, Inc. (EOLS)'s share was trading at $11.76 as of May 7th. EOLS's forward P/E was 117.65 according to Yahoo Finance. ATeam/ Evolus has quickly positioned itself as a disruptive force in the global injectable aesthetics market, traditionally dominated by pharmaceutical giants like AbbVie and Galderma. The company's flagship product, Jeuveau, has gained significant traction, capturing 13% of the U.S. neuromodulator market within just five years. Jeuveau's success can be attributed to its innovative go-to-market strategy, which combines pharmaceutical credibility with direct-to-consumer (DTC) marketing techniques typically associated with the beauty industry. By offering Jeuveau at a price point approximately 20% below Botox, it has been able to resonate with a younger demographic, particularly those between the ages of 20 and 40. This pricing strategy, combined with a robust presence in over 16,000 medical practices—including a growing number of medical spas that lack strong brand loyalty—has made Jeuveau a popular alternative to Botox. This market acceptance has positioned Evolus favorably in the expanding U.S. injectables market, which is undergoing structural changes driven by greater societal acceptance, a wider demographic appeal, and an aging population with increasing disposable income. The broader U.S. injectables market is seeing strong growth, with the popularity of non-invasive cosmetic procedures accelerating. The U.S. is expected to follow more mature markets like Korea, where injectables are already deeply embedded in cosmetic routines. This trend represents a significant growth opportunity for Evolus, which is now at a crucial inflection point in its business development. The company plans to diversify beyond neuromodulators with the upcoming launch of Evolysse, a premium line of dermal fillers developed in partnership with Symatese, the same formulation partner behind Galderma's Restylane. Evolus is seeking FDA approval for several aesthetic indications, including lip and cheek enhancement. This expansion into dermal fillers is expected to contribute approximately $200 million to Evolus' revenue over time, further strengthening its position in the injectables space. Moreover, Evolus is adopting an innovative subscription-based model, 'Club Evolus,' which offers customers quarterly treatments for a monthly fee. This model is designed to drive customer loyalty and predictable revenue streams, providing a clear path to sustained growth. With these initiatives in play, Evolus is targeting annual revenue growth of 25-27%, with projections aiming for $700 million in revenue by 2028, up from an estimated $266 million in 2024. If the company achieves these goals, it expects to reach positive cash flow by 2026. However, despite its promising growth trajectory, Evolus remains a high-risk, high-reward investment. Several factors introduce uncertainty, including regulatory dependencies around product approvals and manufacturing partnerships. Additionally, since all Evolus procedures are out-of-pocket and not covered by insurance, the company's performance is sensitive to broader consumer spending trends. Economic downturns could impact discretionary spending on cosmetic procedures, presenting a potential headwind to growth. Still, if Evolus can continue executing its strategy effectively, maintain rational competition, and convert growth into sustainable profits, the company could deliver significant upside to investors. Furthermore, Evolus' ability to capture market share in the growing injectable aesthetics sector—through innovation, branding, and consumer loyalty—positions it as a compelling investment despite the inherent risks. Evolus stands out among its competitors, particularly Galderma, which, although boasting successful injectable brands like Dysport and Restylane, has a more diluted business model. Galderma also operates legacy divisions, including skincare products like Cetaphil, which is losing ground to competitors like L'Oréal's Cerave, and a dermatological drug pipeline that limits its growth potential. In contrast, Evolus offers a cleaner, more focused investment thesis, solely concentrating on injectable aesthetics. While it is still smaller and must prove long-term profitability, the simplicity of Evolus' business model and its focus on high-growth injectables makes it a more attractive pure-play investment in the sector. Valuing Evolus is complex due to the limited number of direct competitors, but looking at mature self-pay therapeutic companies like Align, Sonova, and Alcon—whose valuations range from 13-17x EV/EBITDA—can provide some context. If Evolus reaches $700 million in revenue by 2028 and delivers an 11% EBITDA margin, which is lower than its 20% long-term target but adjusted for stock-based compensation, the company would generate approximately $77 million in EBITDA. Using a 15x EV/EBITDA multiple, this could result in annualized returns of around 20%, contingent on continued growth. However, key risks remain. Evolus relies on licensing agreements for its neuromodulator Jeuveau from Daewoong and its fillers from Symatese, both of which come with volume requirements and finite durations. Any disruptions to these agreements could create a going concern issue for the company. Moreover, competition from South Korean entrants and a fragmented filler market pose additional risks. As competition intensifies, pricing pressures could erode margins, further complicating Evolus' growth strategy. Another risk comes from tariffs. New U.S. import duties on products from South Korea and France could impact Jeuveau and Evolysse fillers, though they may be exempt as pharmaceuticals. If tariffs do apply, Evolus may need to raise prices by 5-6% to offset the cost increases, which could be manageable given the strong margins and pricing power of its products. Competitors like AbbVie and Galderma may also face similar tariff-related challenges, potentially leveling the playing field. Despite these risks, Evolus benefits from a seasoned management team, including executives with deep experience from Allergan, such as CEO David Moatazedi and CMO Rui Avelar. This leadership, combined with a focused business model and significant upside potential, makes Evolus a standout investment in the injectable aesthetics space. While the company must prove its long-term profitability, its focused approach and market opportunities position it for potential substantial growth in a rapidly expanding industry. Evolus, Inc. (EOLS) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 32 hedge fund portfolios held EOLS at the end of the fourth quarter which was 24 in the previous quarter. While we acknowledge the risk and potential of EOLS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than EOLS but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey.
Yahoo
13-05-2025
- Business
- Yahoo
Evolus, Inc. (EOLS): A Bull Case Theory
We came across a bullish thesis on Evolus, Inc. (EOLS) on Substack by Greg ┃The Elevator Pitch. In this article, we will summarize the bulls' thesis on EOLS. Evolus, Inc. (EOLS)'s share was trading at $11.76 as of May 7th. EOLS's forward P/E was 117.65 according to Yahoo Finance. ATeam/ Evolus has quickly positioned itself as a disruptive force in the global injectable aesthetics market, traditionally dominated by pharmaceutical giants like AbbVie and Galderma. The company's flagship product, Jeuveau, has gained significant traction, capturing 13% of the U.S. neuromodulator market within just five years. Jeuveau's success can be attributed to its innovative go-to-market strategy, which combines pharmaceutical credibility with direct-to-consumer (DTC) marketing techniques typically associated with the beauty industry. By offering Jeuveau at a price point approximately 20% below Botox, it has been able to resonate with a younger demographic, particularly those between the ages of 20 and 40. This pricing strategy, combined with a robust presence in over 16,000 medical practices—including a growing number of medical spas that lack strong brand loyalty—has made Jeuveau a popular alternative to Botox. This market acceptance has positioned Evolus favorably in the expanding U.S. injectables market, which is undergoing structural changes driven by greater societal acceptance, a wider demographic appeal, and an aging population with increasing disposable income. The broader U.S. injectables market is seeing strong growth, with the popularity of non-invasive cosmetic procedures accelerating. The U.S. is expected to follow more mature markets like Korea, where injectables are already deeply embedded in cosmetic routines. This trend represents a significant growth opportunity for Evolus, which is now at a crucial inflection point in its business development. The company plans to diversify beyond neuromodulators with the upcoming launch of Evolysse, a premium line of dermal fillers developed in partnership with Symatese, the same formulation partner behind Galderma's Restylane. Evolus is seeking FDA approval for several aesthetic indications, including lip and cheek enhancement. This expansion into dermal fillers is expected to contribute approximately $200 million to Evolus' revenue over time, further strengthening its position in the injectables space. Moreover, Evolus is adopting an innovative subscription-based model, 'Club Evolus,' which offers customers quarterly treatments for a monthly fee. This model is designed to drive customer loyalty and predictable revenue streams, providing a clear path to sustained growth. With these initiatives in play, Evolus is targeting annual revenue growth of 25-27%, with projections aiming for $700 million in revenue by 2028, up from an estimated $266 million in 2024. If the company achieves these goals, it expects to reach positive cash flow by 2026. However, despite its promising growth trajectory, Evolus remains a high-risk, high-reward investment. Several factors introduce uncertainty, including regulatory dependencies around product approvals and manufacturing partnerships. Additionally, since all Evolus procedures are out-of-pocket and not covered by insurance, the company's performance is sensitive to broader consumer spending trends. Economic downturns could impact discretionary spending on cosmetic procedures, presenting a potential headwind to growth. Still, if Evolus can continue executing its strategy effectively, maintain rational competition, and convert growth into sustainable profits, the company could deliver significant upside to investors. Furthermore, Evolus' ability to capture market share in the growing injectable aesthetics sector—through innovation, branding, and consumer loyalty—positions it as a compelling investment despite the inherent risks. Evolus stands out among its competitors, particularly Galderma, which, although boasting successful injectable brands like Dysport and Restylane, has a more diluted business model. Galderma also operates legacy divisions, including skincare products like Cetaphil, which is losing ground to competitors like L'Oréal's Cerave, and a dermatological drug pipeline that limits its growth potential. In contrast, Evolus offers a cleaner, more focused investment thesis, solely concentrating on injectable aesthetics. While it is still smaller and must prove long-term profitability, the simplicity of Evolus' business model and its focus on high-growth injectables makes it a more attractive pure-play investment in the sector. Valuing Evolus is complex due to the limited number of direct competitors, but looking at mature self-pay therapeutic companies like Align, Sonova, and Alcon—whose valuations range from 13-17x EV/EBITDA—can provide some context. If Evolus reaches $700 million in revenue by 2028 and delivers an 11% EBITDA margin, which is lower than its 20% long-term target but adjusted for stock-based compensation, the company would generate approximately $77 million in EBITDA. Using a 15x EV/EBITDA multiple, this could result in annualized returns of around 20%, contingent on continued growth. However, key risks remain. Evolus relies on licensing agreements for its neuromodulator Jeuveau from Daewoong and its fillers from Symatese, both of which come with volume requirements and finite durations. Any disruptions to these agreements could create a going concern issue for the company. Moreover, competition from South Korean entrants and a fragmented filler market pose additional risks. As competition intensifies, pricing pressures could erode margins, further complicating Evolus' growth strategy. Another risk comes from tariffs. New U.S. import duties on products from South Korea and France could impact Jeuveau and Evolysse fillers, though they may be exempt as pharmaceuticals. If tariffs do apply, Evolus may need to raise prices by 5-6% to offset the cost increases, which could be manageable given the strong margins and pricing power of its products. Competitors like AbbVie and Galderma may also face similar tariff-related challenges, potentially leveling the playing field. Despite these risks, Evolus benefits from a seasoned management team, including executives with deep experience from Allergan, such as CEO David Moatazedi and CMO Rui Avelar. This leadership, combined with a focused business model and significant upside potential, makes Evolus a standout investment in the injectable aesthetics space. While the company must prove its long-term profitability, its focused approach and market opportunities position it for potential substantial growth in a rapidly expanding industry. Evolus, Inc. (EOLS) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 32 hedge fund portfolios held EOLS at the end of the fourth quarter which was 24 in the previous quarter. While we acknowledge the risk and potential of EOLS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than EOLS but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
18-02-2025
- Business
- Yahoo
Evolus to Report Fourth Quarter and Year End 2024 Results on March 4, 2025
NEWPORT BEACH, Calif., February 18, 2025--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its fourth quarter and year end 2024 financial results on Tuesday, March 4, 2025, after the U.S. financial markets close. Evolus management will host a conference call and live webcast to discuss these results at 4:30 p.m. ET that same day. A question-and-answer session will follow management's remarks. To participate in the conference call, dial (877) 407-6184 (U.S.) or (201) 389-0877 (international) or connect live via webcast on the Investor Relations page of the Evolus website here. Following the completion of the call, a telephonic replay can be accessed by dialing (877) 660-6853 (U.S.) or (201) 612-7415 (international) and using conference number 13751816. An archived webcast can also be accessed on the Investor Relations page of the Evolus website at About Evolus, Inc. Evolus (NASDAQ: EOLS) is a global performance beauty company redefining the aesthetic injectable market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global leader in aesthetics anchored by our flagship products: Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics, and Evolysse™, a collection of unique injectable hyaluronic acid (HA) gels. Visit us at and follow us on LinkedIn, X, Instagram or Facebook. Jeuveau® and Nuceiva®, are registered trademarks and Evolysse™ is a trademark of Evolus, Inc. View source version on Contacts Investors: Nareg Sagherian, Vice President, Head of Global Investor Relations and Corporate CommunicationsPhone: (248) 202-9267Email: ir@ Media:Email: media@ Sign in to access your portfolio
Yahoo
10-02-2025
- Business
- Yahoo
With 70% ownership, Evolus, Inc. (NASDAQ:EOLS) boasts of strong institutional backing
Institutions' substantial holdings in Evolus implies that they have significant influence over the company's share price The top 11 shareholders own 50% of the company Ownership research along with analyst forecasts data help provide a good understanding of opportunities in a stock A look at the shareholders of Evolus, Inc. (NASDAQ:EOLS) can tell us which group is most powerful. With 70% stake, institutions possess the maximum shares in the company. Put another way, the group faces the maximum upside potential (or downside risk). Because institutional owners have a huge pool of resources and liquidity, their investing decisions tend to carry a great deal of weight, especially with individual investors. As a result, a sizeable amount of institutional money invested in a firm is generally viewed as a positive attribute. Let's delve deeper into each type of owner of Evolus, beginning with the chart below. Check out our latest analysis for Evolus Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices. Evolus already has institutions on the share registry. Indeed, they own a respectable stake in the company. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Evolus' historic earnings and revenue below, but keep in mind there's always more to the story. Institutional investors own over 50% of the company, so together than can probably strongly influence board decisions. Evolus is not owned by hedge funds. Looking at our data, we can see that the largest shareholder is Perceptive Advisors LLC with 8.5% of shares outstanding. Tang Capital Management, LLC is the second largest shareholder owning 7.7% of common stock, and BlackRock, Inc. holds about 6.9% of the company stock. After doing some more digging, we found that the top 11 have the combined ownership of 50% in the company, suggesting that no single shareholder has significant control over the company. While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. There are plenty of analysts covering the stock, so it might be worth seeing what they are forecasting, too. The definition of an insider can differ slightly between different countries, but members of the board of directors always count. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO. Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group. Shareholders would probably be interested to learn that insiders own shares in Evolus, Inc.. As individuals, the insiders collectively own US$16m worth of the US$830m company. It is good to see some investment by insiders, but it might be worth checking if those insiders have been buying. With a 11% ownership, the general public, mostly comprising of individual investors, have some degree of sway over Evolus. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies. With an ownership of 8.5%, private equity firms are in a position to play a role in shaping corporate strategy with a focus on value creation. Sometimes we see private equity stick around for the long term, but generally speaking they have a shorter investment horizon and -- as the name suggests -- don't invest in public companies much. After some time they may look to sell and redeploy capital elsewhere. Our data indicates that Private Companies hold 3.4%, of the company's shares. Private companies may be related parties. Sometimes insiders have an interest in a public company through a holding in a private company, rather than in their own capacity as an individual. While it's hard to draw any broad stroke conclusions, it is worth noting as an area for further research. Public companies currently own 5.0% of Evolus stock. This may be a strategic interest and the two companies may have related business interests. It could be that they have de-merged. This holding is probably worth investigating further. It's always worth thinking about the different groups who own shares in a company. But to understand Evolus better, we need to consider many other factors. Consider for instance, the ever-present spectre of investment risk. We've identified 1 warning sign with Evolus , and understanding them should be part of your investment process. Ultimately the future is most important. You can access this free report on analyst forecasts for the company. NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Yahoo
09-02-2025
- Business
- Yahoo
Muskogee Public Library aims for funding, growth
Muskogee Public Library Branch Manager Julie Poor said she dreams of serving twice as many visitors than the 81,314 who visited last year. 'I love that people want to come and use the library,' Poor said. 'I love that people want to see this as a stopping place for them.' However, the library must address many problems before those dreams come true, officials said. For example, a boiler/chiller and a public elevator have not been replaced for 52 years and are in constant need of repair, Poor said. The library, part of Eastern Oklahoma Library System, seeks funding to meet immediate needs and long-term goals, said Kathy Seibold, system executive director. The system is embarking on an Imagine More fundraising campaign raise at least $8 million for an eventual library renovation. Seibold said the library will first seek major funding sources, including potential sales tax revenue. A second phase would include gifts between $50,000 to $500,000, a third phase could include community donations. She said fundraising could take three years. Oklahoma libraries are funded mostly through city funds and county taxes, she said. Cities pay the utilities, insurance and building maintenance. The city of Muskogee allocated $65,000 for the library out of its 2024-25 budget, Seibold said. Counties provide ad valorem tax to libraries. Muskogee County provides four mills for library services throughout the county, Seibold said. Other libraries in the county are in Warner, Fort Gibson and Haskell. 'This year, Muskogee County provided $2,308,834.74 for the entire county,' Seibold said. 'EOLS uses ad valorem revenue to provide staff, materials and programming for the libraries in the system. Muskogee Public Library's individual budget is $1,238,627.' Major library repairs were part of a city sales tax proposed for 2024 public vote. The election, along with a larger bond issue, were later scrapped. The sales tax proposal, to replace the half-cent sales tax expiring this October, included $1.5 million for HVAC and interior improvements at the library. The city formed a committee to plan projects for a 2025 sales tax vote. The library wants to be a part of that sales tax proposal for at least $1.5 million, Seibold said. Poor said the library has many age-related problems. She said the public elevator failed to operate 13 times in the past year. Water leaks from the downstairs chiller, which dates to the library's opening. Poor said it's hard to get parts for a unit that old. 'This becomes a huge issue,' Poor said. 'The summer before last, we were shut down 13 days. The highest we got was 91 degrees inside the library.' Floors are cracking in the lobby. Carpet is soiled upstairs and downstairs. Seibold said the library eventually will need a total remodel. 'We would take it down to the studs,' she said. 'We have some restrooms that are not active right now because of the plumbing is not good. It needs new electrical, new HVAC. Those things alone would be $3 million.' Poor said library employees discussed what they wanted Muskogee Library to be. Suggestions included more Maker Space for 3D printing and other computer-assisted projects. 'We want to meet the needs of today's patron,' Siebold said. 'Which means more community space. More space for one-on-one meetings, small rooms for teachers to meet with students.' Artist renderings include outdoor spaces, such as a balcony, meeting area and children's space. Seibold said the library would retain its mid-century modern style. 'That was something very important to us,' she said. 'They love this library. They love this building. There has been talk about building a new building. People said 'No.' It's important to them and important to us to maintain the style that this is, but bring it to today.'
